Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Age-related Macular Degeneration: early-phase trial registry
20 of 75 indexed Age-related Macular Degeneration trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #178 of 28,707 conditions by registered trial count.
75 US clinical trials · 20 currently recruiting · #178 of 28,707 conditions by registered trial count
Age-related Macular Degeneration: 75 US clinical trials tracked, 20 recruiting.
Age-related Macular Degeneration is the subject of 75 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 8 of these trials.
Enrollment posture brief
Registry condition age-related-macular-degeneration
OPEN 20 | RECR 27% | LATE 8 | EARLY 26 | RANK #178 | SPON 8
Volume-matched condition peers
Nearest open-share peer: AIDS (27% recruiting · 15 trials)
Age-related Macular Degeneration lists 20 open slots (27% of 75 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Age-related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Age-related Macular Degeneration is recruiting below its size-band peers.
20 of 75 indexed trials (26.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Age-related Macular Degeneration trials is spread across many organizations.
National Eye Institute (NEI) accounts for 8 of 75 trials (10.7%). 53 distinct sponsors appear on at least one study for this condition label.
-
Typical Age-related Macular Degeneration enrolment sits around 79 participants.
Median target enrolment is 79 among the 75 trials that report a genuine target (sentinel values excluded). 42 of those (56%) plan for fewer than 100 participants.
-
Age-related Macular Degeneration splits between interventional and observational designs.
48 interventional and 27 observational studies make up this index (64% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
75 total, page 1 of 2
Village-Integrated Eye Worker Trial II
University of California, San Francisco
NCT03752840
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
NCT05635266
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
University of Wisconsin, Madison
NCT06924021
National Eye Institute Biorepository for Retinal Diseases
National Eye Institute (NEI)
NCT01496625
High Resolution Retinal Imaging
University of Pennsylvania
NCT01866371
Stem Cell Ophthalmology Treatment Study II
MD Stem Cells
NCT03011541
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Hoffmann-La Roche
NCT06961370
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
VisionCare
NCT05438732
Progression of Early Atrophic Lesions
University of Utah
NCT05959005
Visual Remapping to Aid Reading With Field Loss
University of Minnesota
NCT03848663
Adaptive Optics Imaging of Outer Retinal Diseases
Food and Drug Administration (FDA)
NCT05355415
AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
Duke University
NCT06619405
Lutein, Zeaxathin, and Fish Oil Supplementation
Texas A&M University
NCT06489873
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
AbbVie
NCT07160179
Effects of Goji vs. Fiber on Macular Degeneration
University of California, Davis
NCT06237127
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Perceive Biotherapeutics
NCT06087458
The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma
MCPHS University
NCT06593405
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Astellas Institute for Regenerative Medicine
NCT03178149
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
Massachusetts Eye and Ear Infirmary
NCT04735263
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
University of Rochester
NCT06319872
ForeseeHome NRich Registry
Notal Vision
NCT05690880
GARM II: A Study on the Genetics of Age-related Maculopathy
University of California, Los Angeles
NCT01115387
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Genentech
NCT05300724
Study of Dark Adaptation in Age-Related Macular Degeneration
National Eye Institute (NEI)
NCT01352975
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Novartis Pharmaceuticals
NCT05230537
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
Western University of Health Sciences
NCT05763940
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics
NCT05112861
Age-Related Eye Disease Study (AREDS) Follow-Up
National Eye Institute (NEI)
NCT00594672
Impact of Non-Exudative Type 1 MNV on AMD Progression
University of Utah
NCT06125977
Dark Adaptation in Participants With Age-Related Macular Degeneration
National Eye Institute (NEI)
NCT03225131
A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)
Icahn School of Medicine at Mount Sinai
NCT03963817
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Perceive Biotherapeutics
NCT05380492
Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
Michelle Abou-Jaoude
NCT06164587
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Chengdu Origen Biotechnology Co.
NCT05657301
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Hoffmann-La Roche
NCT02286089
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
Elisigen
NCT05984927
A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
Oxford BioMedica
NCT01678872
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Chengdu Origen Biotechnology Co.
NCT06825858
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
University of Pennsylvania
NCT00593450
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
Novartis Pharmaceuticals
NCT04005352
Functionally Validated Structural Endpoints for Early AMD
Cynthia Owsley
NCT04112667
AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study
Duke University
NCT00734487
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics
NCT03834753
Phase 2/3 Study of ALK-001 in Geographic Atrophy
Alkeus Pharmaceuticals
NCT03845582
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics
NCT04516278
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Stealth BioTherapeutics
NCT03891875
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
Sequenom
NCT01880788
Genetic Study of Age-Related Macular Degeneration
National Eye Institute (NEI)
NCT00357578
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
Lawrence S. Morse, MD
NCT00931489
Study on Visual Function Impairments in Dry Age-related Macular Degeneration
Duke University
NCT01822873
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 8 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Age-related Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Age-related Macular Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Age-related Macular Degeneration page
75 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Age-related Macular Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Age-related Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Age-related Macular Degeneration condition card totals 75 registered trials; most-linked intervention bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.